Press Releases July 2nd, 2025: MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease…MaaT PharmaJuly 2, 2025
Press Releases June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…MaaT PharmaJune 19, 2025
Press Releases June 13, 2025: MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…MaaT PharmaJune 13, 2025
Press Releases June 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…MaaT PharmaJune 2, 2025
Press Releases May 14, 2025: MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…MaaT PharmaMay 14, 2025
Press Releases May 13, 2025: MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 Positive…MaaT PharmaMay 13, 2025
Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…MaaT PharmaMarch 31, 2025
Press Releases March 27, 2025: MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024…MaaT PharmaMarch 27, 2025
Press Releases March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…MaaT PharmaMarch 18, 2025